| 000 | 01905 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250514190355.0 | ||
| 264 | 0 | _c20040625 | |
| 008 | 200406s 0 0 eng d | ||
| 022 | _a0009-9104 | ||
| 024 | 7 |
_a10.1111/j.1365-2249.2004.02476.x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aTorre, F | |
| 245 | 0 | 0 |
_aKinetics of soluble tumour necrosis factor (TNF)-alpha receptors and cytokines in the early phase of treatment for chronic hepatitis C: comparison between interferon (IFN)-alpha alone, IFN-alpha plus amantadine or plus ribavirin. _h[electronic resource] |
| 260 |
_bClinical and experimental immunology _cJun 2004 |
||
| 300 |
_a507-12 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAmantadine _xtherapeutic use |
| 650 | 0 | 4 |
_aAntiviral Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aBiomarkers _xblood |
| 650 | 0 | 4 | _aCombined Modality Therapy |
| 650 | 0 | 4 |
_aCytokines _xmetabolism |
| 650 | 0 | 4 |
_aEnzyme-Linked Immunosorbent Assay _xmethods |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aHepatitis C, Chronic _xdrug therapy |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aImmunotherapy, Active |
| 650 | 0 | 4 |
_aInterferon-alpha _xadministration & dosage |
| 650 | 0 | 4 |
_aInterferon-gamma _xblood |
| 650 | 0 | 4 |
_aInterleukin-10 _xblood |
| 650 | 0 | 4 |
_aInterleukin-12 _xblood |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aReceptors, Tumor Necrosis Factor _xblood |
| 650 | 0 | 4 |
_aRibavirin _xtherapeutic use |
| 650 | 0 | 4 | _aStatistics, Nonparametric |
| 650 | 0 | 4 |
_aTumor Necrosis Factor-alpha _xmetabolism |
| 650 | 0 | 4 | _aViral Load |
| 700 | 1 | _aRossol, S | |
| 700 | 1 | _aPelli, N | |
| 700 | 1 | _aBasso, M | |
| 700 | 1 | _aDelfino, A | |
| 700 | 1 | _aPicciotto, A | |
| 773 | 0 |
_tClinical and experimental immunology _gvol. 136 _gno. 3 _gp. 507-12 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/j.1365-2249.2004.02476.x _zAvailable from publisher's website |
| 999 |
_c14856314 _d14856314 |
||